Nature of Business (Details)				1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 09, 2024 USD ($) $ / shares shares	Jun. 05, 2024 shares	Apr. 22, 2024 USD ($) $ / shares shares	Nov. 01, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment $ / shares shares	Sep. 30, 2023 USD ($)	Jul. 10, 2024 $ / shares	Jul. 08, 2024 $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Nature of business:
Number of operating segments | segment							2
Accumulated deficit					$ 230,983,386		$ 230,983,386				$ 225,704,176
Net Income (Loss)					(1,719,381)	$ (1,662,702)	(5,279,210)	$ (4,320,835)
Net cash used in operating activities							(6,170,761)	(6,775,896)
Cash and cash equivalents					9,840,177	$ 10,298,534	9,840,177	10,298,534			8,446,158	$ 13,359,615
Working capital					5,776,645		5,776,645				$ 3,355,212
Shares issued price per share | $ / shares			$ 6.40
Percentage of numbers of shares issued upon exercise of existing warrants	150.00%
Reverse stock spilt effective from June 5, 2024		0.0625
Fractional shares issued in reverse stock split (in shares) | shares		0
Public Offering
Nature of business:
Exercise price of warrants | $ / shares			$ 0.02
Expiration term of warrants			5 years
Total gross proceeds			$ 4,750,000
Issuance costs			$ 450,000				625,065	834,061
At Market Issuance sales
Nature of business:
Issuance costs					$ 1,947		$ 1,947	$ 95,348
Common Stock
Nature of business:
Fractional shares issued in reverse stock split (in shares) | shares							114,735
Common Stock | Public Offering
Nature of business:
Number of shares issued | shares			204,694
Exercise price of warrants | $ / shares			$ 6.40
Common Stock | At Market Issuance sales
Nature of business:
Number of shares issued | shares					14,883		14,883
Weighted average price | $ / shares							$ 3.93
Subsequent Event | At Market Issuance sales
Nature of business:
Number of shares issued | shares				229,078
Total gross proceeds				$ 1,100,000
Aggregate value of shares remaining from agreement				$ 4,700,000
Weighted average price | $ / shares				$ 4.72
Pre-funded warrants | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares			537,500
Common warrants | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares			742,194
Existing Warrants
Nature of business:
Number of common warrants to purchase shares issued | shares	703,125
Exercise price of warrants | $ / shares	$ 6.00									$ 6.40
Proceeds from the exercise of pre-funded warrants	$ 4,200,000
Existing Warrants | Common Stock
Nature of business:
Exercise price of warrants | $ / shares									$ 6.00
HyBryte
Nature of business:
Revenue from collaborative arrangement							$ 1,100,000
Term (in years)							4 years
NIH
Nature of business:
Government grant funding					$ 554,000		$ 554,000